Read the methods. Keep the boundaries.

Preclinical-dominant evidenceTechnical brief

BPC-157: Identity, Evidence, and Documentation

A source-backed research brief covering BPC-157 identity, model-system evidence, interpretation limits, and lot documentation.

Synthetic pentadecapeptideRead brief →

Primarily cell and material-system evidenceTechnical brief

GHK-Cu: Identity, Evidence, and Documentation

A source-backed research brief covering GHK-Cu identity, model-system evidence, interpretation limits, and lot documentation.

Copper(II) complex of a tripeptideRead brief →

Mechanistic and animal-model evidenceTechnical brief

Selank: Identity, Evidence, and Documentation

A source-backed research brief covering Selank identity, model-system evidence, interpretation limits, and lot documentation.

Synthetic tuftsin-derived heptapeptideRead brief →

Mechanistic and animal-model evidenceTechnical brief

Semax: Identity, Evidence, and Documentation

A source-backed research brief covering Semax identity, model-system evidence, interpretation limits, and lot documentation.

Synthetic ACTH(4–10)-derived heptapeptideRead brief →

Identity-sensitive preclinical evidenceTechnical brief

TB-500: Identity, Evidence, and Documentation

A source-backed research brief covering TB-500 identity, model-system evidence, interpretation limits, and lot documentation.

Thymosin-β4 fragment research peptideRead brief →

Extensive drug literature; strict material boundaryTechnical brief

Tirzepatide: Identity, Evidence, and Documentation

A source-backed research brief covering Tirzepatide identity, model-system evidence, interpretation limits, and lot documentation.

Acylated dual GIP/GLP-1 receptor agonist peptideRead brief →